The Surgical Management of Brain Metastases in Non-Small Cell Lung Cancer (NSCLC): Identification of the Early Laboratory and Clinical Determinants of Survival.
brain metastases
lung cancer
overall survival
surgical management
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
05 Sep 2021
05 Sep 2021
Historique:
received:
07
08
2021
revised:
23
08
2021
accepted:
02
09
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
Brain metastases (BM) indicate advanced states of cancer disease and cranial surgery represents a common treatment modality. In the present study, we aimed to identify the risk factors for a reduced survival in patients receiving a surgical treatment of BM derived from non-small cell lung cancer (NSCLC). A total of 154 patients with NSCLC that had been surgically treated for BM at the authors' institution between 2013 and 2018 were included for a further analysis. A multivariate analysis was performed to identify the predictors of a poor overall survival (OS). The median overall survival (mOS) was 11 months (95% CI 8.2-13.8). An age > 65 years, the infratentorial location of BM, elevated preoperative C-reactive protein levels, a perioperative red blood cell transfusion, postoperative prolonged mechanical ventilation (>48 h) and the occurrence of postoperative adverse events were identified as independent factors of a poor OS. The present study identified several predictors for a worsened OS in patients that underwent surgery for BM of NSCLC. These findings might guide a better risk/benefit assessment in the course of metastatic NSCLC therapy and might help to more sufficiently cope with the challenges of cancer therapy in these advanced stages of disease.
Sections du résumé
BACKGROUND
BACKGROUND
Brain metastases (BM) indicate advanced states of cancer disease and cranial surgery represents a common treatment modality. In the present study, we aimed to identify the risk factors for a reduced survival in patients receiving a surgical treatment of BM derived from non-small cell lung cancer (NSCLC).
METHODS
METHODS
A total of 154 patients with NSCLC that had been surgically treated for BM at the authors' institution between 2013 and 2018 were included for a further analysis. A multivariate analysis was performed to identify the predictors of a poor overall survival (OS).
RESULTS
RESULTS
The median overall survival (mOS) was 11 months (95% CI 8.2-13.8). An age > 65 years, the infratentorial location of BM, elevated preoperative C-reactive protein levels, a perioperative red blood cell transfusion, postoperative prolonged mechanical ventilation (>48 h) and the occurrence of postoperative adverse events were identified as independent factors of a poor OS.
CONCLUSIONS
CONCLUSIONS
The present study identified several predictors for a worsened OS in patients that underwent surgery for BM of NSCLC. These findings might guide a better risk/benefit assessment in the course of metastatic NSCLC therapy and might help to more sufficiently cope with the challenges of cancer therapy in these advanced stages of disease.
Identifiants
pubmed: 34501461
pii: jcm10174013
doi: 10.3390/jcm10174013
pmc: PMC8432449
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 2016 Jan 10;34(2):123-9
pubmed: 26438117
Cancers (Basel). 2020 Oct 31;12(11):
pubmed: 33142701
Asian Cardiovasc Thorac Ann. 2014 Jan;22(1):55-64
pubmed: 24585645
Handb Clin Neurol. 2018;149:27-42
pubmed: 29307358
J Neurooncol. 2019 Oct;145(1):143-150
pubmed: 31485921
Gynecol Oncol. 2018 Nov;151(2):294-298
pubmed: 30201233
Curr Oncol. 2008 Oct;15(5):25-45
pubmed: 19008990
Br J Cancer. 2014 Sep 9;111(6):1222-9
pubmed: 25051406
Clin Lung Cancer. 2017 Nov;18(6):607-614
pubmed: 28571688
JAMA Oncol. 2019 Feb 1;5(2):243-247
pubmed: 30419088
Br J Anaesth. 2013 May;110(5):690-701
pubmed: 23599512
Anesthesiology. 2008 Dec;109(6):989-97
pubmed: 19034095
Br J Cancer. 2004 Dec 13;91(12):2018-25
pubmed: 15545971
Lung Cancer. 2013 Jan;79(1):1-7
pubmed: 23137549
Crit Care. 2013 Jul 22;17(4):R144
pubmed: 23876301
Cancer Treat Rev. 2016 Apr;45:139-62
pubmed: 27019457
Neurosurg Rev. 2020 Feb;43(1):211-216
pubmed: 30219955
Chest. 2004 Feb;125(2):597-606
pubmed: 14769744
Neurosurg Rev. 2021 Apr;44(2):1023-1029
pubmed: 32212047
Nat Rev Dis Primers. 2019 Jan 17;5(1):5
pubmed: 30655533
Transl Lung Cancer Res. 2016 Oct;5(5):554-556
pubmed: 27827463
CNS Drugs. 2002;16(5):325-38
pubmed: 11994022
Ann Surg Oncol. 2012 Mar;19(3):1043-50
pubmed: 21861219
Oncol Rep. 1994 Nov;1(6):1203-5
pubmed: 21607516
J Neurooncol. 2020 Sep;149(3):455-461
pubmed: 32990861
Neurosurg Rev. 2020 Apr;43(2):483-495
pubmed: 30058049
Cancer Med. 2020 Oct;9(20):7503-7510
pubmed: 32858763
Neurooncol Adv. 2020 Jan-Dec;2(1):vdaa041
pubmed: 32363344
J Clin Oncol. 2016 Apr 10;34(11):1223-30
pubmed: 26834066